Need for a proactive and structured approach to risk analysis when designing phase I trials.

22 July 2015. doid: 10.1136/bmj.h3899

Van den Bogert CA, Cohen AF

View publication

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

contact